Ongoing Assessments & Recent Research.
Easy access to our work
Anemia in Myelodysplastic Syndrome
Jul 2024Post-Traumatic Stress Disorder
May 2024Recent Milestones
Please find the Midwest CEPAC’s 2024 public meeting on ensifentrine below:
The topic of diversity in clinical trials is rising to the forefront of many conversations in evidence-based medicine, and efforts are being made to improve the diversity of clinical trials. However, there is little uniformity in the methods used to evaluate these efforts.
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Groups such as Health Technology Assessment bodies, clinical trial regulators, policymakers, journal editors, and individual researchers can use this tool to examine, monitor, and improve diversity in clinical trials.
Register here for the CTAF’s July 19th public meeting on imetelstat. The revised Evidence Report, which will be the basis for this meeting, will be published on July 2nd.
Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review Publishes Protocol for Annual Assessment of Drug Coverage Policies That Present Barriers to Fair Access
This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs reviewed by ICER in 2022; data obtained from payers, MMIT’s Market Access Analytics solution, and IQVIA will be leveraged to perform the analyses.
06/05/2024Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Chronic Obstructive Pulmonary Disease
Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds for cost-effectiveness if priced between $7,500 to $12,700 per year.
05/30/2024Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Post-Traumatic Stress Disorder
There are substantial uncertainties around the clinical trial results; given the inability to assess net benefit, ICER will not recommend a health-benefit price benchmark.
05/14/2024Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Key
Developments.
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
In early 2024, NICE announced a collaboration with ICER, CADTH, and ZIN (also known as the National Healthcare Institute in the Netherlands) to share learnings about the development of economic models at the disease level (rather than product level). Learn more about the initiative here.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
ICER’s third annual “Barriers to Fair Access” assessment of prescription drug coverage policies within US commercial insurance, and the Veterans Health Administration. The analysis found that major payer coverage policies for 18 drugs often met fair access criteria for cost sharing, clinical eligibility, step therapy, and provider restrictions.
However, the report’s findings suggest that major improvements are needed in the transparency of coverage policy information for consumers, and in detailing out-of-pocket costs for patients.
Unsupported Price Increases
Of 10 high-expenditure drugs that had substantial 2022 net price increases, eight were not supported by new clinical evidence; these increases accounted for $1.27 billion in additional costs over one year.
Additionally, one of three Medicare Part B drugs with high list price increases in 2021 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $680 per year
Managing the Challenges of Paying for Gene Therapy
An analysis of policy reforms and market actions to support innovation and access while managing uncertainty, affordability, and equity concerns; developed as part of ICER’s Policy Leadership Forum with input from diverse stakeholders.